Shots:
- Sling Therapeutics has dosed the first patients in the global P-III (ORBIT) trial assessing linsitinib (150mg, PO, BID) vs PBO in ~130 adults with mod. to sev. active thyroid eye disease (TED) for 24wks.
- The trial will assess the proportion of proptosis responders at Wk. 24, defined as a ≥2 mm reduction in the study eye without worsening in the fellow eye, as the 1EP. Pts will be eligible to enter 24wk. OLE after the PBO-controlled period
- Linsitinib is a small-molecule therapy in development for TED that inhibits IGF-1R, a target whose activation contributes to inflammation & proptosis
Ref: Businesswire | Image: Sling Therapeutics | Press Release
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
